Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.

SecurityUONE / Urban One, Inc. (75040P405)
IndustryRadio Broadcasting Stations
Institutional Owners9
Institutional Shares2,221,649 - 5.41%
Common Shares Outstanding441,102,708 shares (as of 2018-03-31)
Institutional Value$ 6,323,000 USD
Related 75040PAS7 / Radio One, Inc. 7.375% Bond due 2022-04-15
UONEK / Urban One, Inc. Class D

Institutional Stock Ownership and Shareholders()

UONE / Urban One, Inc. Institutional Ownership

Urban One, Inc. (NASDAQ:UONE) has 9 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,221,649 shares. Largest shareholders include BlackRock Institutional Trust Company, N.A., BlackRock Fund Advisors, Renaissance Technologies LLC, BlackRock Investment Management, LLC, Northern Trust Corp, Mariner Investment Group Llc, BlackRock Advisors LLC, UBS Group AG, BlackRock Inc., and BlackRock Fund Advisors.
Urban One, Inc. (NASDAQ:UONE) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href=""><img src="" alt="UONE / Urban One, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Prev Value
Current Value
2017-02-10 13F-HR BlackRock Advisors LLC 9,139 7,163 -21.62 28 21 -25.00
2018-05-11 13F-HR MARINER INVESTMENT GROUP LLC 13,930 13,930 0.00 26 29 11.54
2018-05-09 13F-HR BlackRock Inc. 233 233 0.00 0 0
2017-02-10 13F-HR BlackRock Fund Advisors 785,836 233 -99.97 2,279 1 -99.96
2017-02-10 13F-HR BlackRock Investment Management, LLC 85,840 85,840 0.00 260 249 -4.23
2017-02-10 13F-HR BlackRock Fund Advisors 233 785,836 337,168.67 1 2,279 227,800.00
2018-05-15 13F-HR UBS Group AG 1,583 1,976 24.83 3 4 33.33
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 1,206,746 1,206,746 0.00 3,656 3,500 -4.27
2018-05-14 13F-HR Renaissance Technologies LLC 100,300 100,300 0.00 186 201 8.06
2018-05-09 13F-HR NORTHERN TRUST CORP 19,392 19,392 0.00 36 39 8.33
2018-05-15 13F-HR HBK Sorce Advisory LLC 21,041 0 -100.00 39 0 -100.00

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Toronto Humane Society children's reading program goes to the dogs

The Toronto Humane Society's Book Buddies Reading Program pairs children who are learning to read with shelter dogs, helping both kids and animals deal with their respective challenges. (3-0)

HT Media and Next Mediaworks propose merger of radio arms

2018-07-18 livemint
HT Media Ltd and Next Mediaworks Ltd on Wednesday announced the signing of the binding term sheet for the proposed merger of their radio arms. This arrangement of course is subject to approval of the final scheme by the Board of Directors and Shareholders at both sides along with all the regulatory approvals. (3-0)

City urged to consider new approach to address gun violence

"Oh my gosh, it's so much. It's so many, I'm tired of them. It's like one after the other after the other," says Brown. (3-0)

Germ-blasting robot sets its sights on fighting C. difficile outbreaks

The Mississauga company behind a robot that blasts away hospital germs using ultraviolet light says its Solaris Lytbot is the ideal weapon in the war against hospital-acquired infections such as C. difficile. (3-0)

Why Trump's trade war makes sense — if you're Trump

If one word could sum up how many Canadians feel about the Trump-shaped piano dangling over the country's economy, it would likely be "disbelief." (6-0)

CUSIP: 75040P405